Skip to main content
Top
Published in: Endocrine 3/2021

01-06-2021 | Pituitary Adenoma | Original Article

True hyperprolactinemia in men without visible pituitary adenoma

Authors: Ilan Shimon, Yaron Rudman, Yossi Manisterski, Alex Gorshtein, Hiba Masri, Hadar Duskin-Bitan

Published in: Endocrine | Issue 3/2021

Login to get access

Abstract

Purpose

Men with mild to moderate hyperprolactinemia rarely present with normal pituitary on MRI with no visible adenoma, a condition entitled also “idiopathic hyperprolactinemia” or “non-tumoral hyperprolactinemia”. We have characterized a cohort of hyperprolactinemic men with normal pituitary imaging.

Design

We have identified 13 men with true hyperprolactinemia and normal pituitary MRI. Baseline clinical and hormonal characteristics and response to medical treatment were retrospectively retrieved from medical records.

Results

Mean age at diagnosis was 51 ± 16 years (range, 20–77); mean serum prolactin level at presentation was 91 ng/ml (range, 28–264), eight men presented with low baseline testosterone. Initial complaints leading to diagnosis included sexual dysfunction in ten men and gynecomastia in five. All patients were treated with cabergoline, except for one who was given bromocriptine; none required pituitary surgery. All patients normalized prolactin and testosterone with subsequent clinical improvement reported by most men. Currently, after a mean follow-up of 72 months, ten patients continue treatment with caborgoline (median weekly dose, 0.25 mg), whereas three men discontinued treatment.

Conclusions

Men with symptomatic hyperprolactinemia may rarely present with normal pituitary imaging. Medical treatment can lead to hormonal improvement with clinical benefit.
Literature
1.
go back to reference M.P. Gillam, M.E. Molitch, G. Lombardi, A. Colao, Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485–534 (2006)CrossRef M.P. Gillam, M.E. Molitch, G. Lombardi, A. Colao, Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485–534 (2006)CrossRef
2.
go back to reference T. Mindermann, C.B. Wilson, Age-related and gender-related occurrence of pituitary adenomas. Clin. Endocrinol. 41, 359–364 (1994)CrossRef T. Mindermann, C.B. Wilson, Age-related and gender-related occurrence of pituitary adenomas. Clin. Endocrinol. 41, 359–364 (1994)CrossRef
3.
go back to reference H. Duskin-Bitan, I. Shimon, Prolactinomas in males: any differences? Pituitary 23, 52–57 (2020)CrossRef H. Duskin-Bitan, I. Shimon, Prolactinomas in males: any differences? Pituitary 23, 52–57 (2020)CrossRef
4.
go back to reference P. Chanson, D. Maiter, The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best. Pract. Res. Clin. Endocrinol. Metab. 33, 101290 (2019)CrossRef P. Chanson, D. Maiter, The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best. Pract. Res. Clin. Endocrinol. Metab. 33, 101290 (2019)CrossRef
5.
go back to reference J. Webster, G. Piscitelli, A. Polli, C.I. Ferrari, I. Ismail, M.F. Scanlon, A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N. Eng. J. Med. 331, 904–909 (1994)CrossRef J. Webster, G. Piscitelli, A. Polli, C.I. Ferrari, I. Ismail, M.F. Scanlon, A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N. Eng. J. Med. 331, 904–909 (1994)CrossRef
6.
go back to reference A. Colao, A.D. Sarno, P. Cappabianca, F. Briganti, R. Pivonello, C.D. Somma, A. Faggiano, B. Biondi, G. Lombardi, Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur. J. Endocrinol. 148, 325–331 (2003)CrossRef A. Colao, A.D. Sarno, P. Cappabianca, F. Briganti, R. Pivonello, C.D. Somma, A. Faggiano, B. Biondi, G. Lombardi, Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur. J. Endocrinol. 148, 325–331 (2003)CrossRef
7.
go back to reference A.M. Lenz, A.W. Root, Empty sella syndrome. Ped. Endocrinol. Rev. 9, 710–715 (2012) A.M. Lenz, A.W. Root, Empty sella syndrome. Ped. Endocrinol. Rev. 9, 710–715 (2012)
8.
go back to reference E. Horvath, K. Kovacs, B.W. Scheithauer, Pituitary hyperplasia. Pituitary 1, 169–179 (1999)CrossRef E. Horvath, K. Kovacs, B.W. Scheithauer, Pituitary hyperplasia. Pituitary 1, 169–179 (1999)CrossRef
9.
go back to reference J. Schlechte, K. Dolan, B. Sherman, F. Chapler, A. Luciano, The natural history of untreated hyperprolactinemia: a prospective analysis. J. Clin. Endocrinol. Metab. 68, 412–418 (1989)CrossRef J. Schlechte, K. Dolan, B. Sherman, F. Chapler, A. Luciano, The natural history of untreated hyperprolactinemia: a prospective analysis. J. Clin. Endocrinol. Metab. 68, 412–418 (1989)CrossRef
10.
go back to reference A.K. Kalsi, A. Halder, M. Jain, P.K. Chaturvedi, J.B. Sharma, Prevalence and reproductive manifestations of macroprolactinemia. Endocrine 63, 332–340 (2019)CrossRef A.K. Kalsi, A. Halder, M. Jain, P.K. Chaturvedi, J.B. Sharma, Prevalence and reproductive manifestations of macroprolactinemia. Endocrine 63, 332–340 (2019)CrossRef
11.
go back to reference O.M. Hauache, A.J. Rocha, A.C. Maia Jr, R.M. Maciel, J.G. Vieira, Screening for macroprolactinaemia and pituitary imaging studies. Clin. Endocrinol. 57, 327–331 (2002)CrossRef O.M. Hauache, A.J. Rocha, A.C. Maia Jr, R.M. Maciel, J.G. Vieira, Screening for macroprolactinaemia and pituitary imaging studies. Clin. Endocrinol. 57, 327–331 (2002)CrossRef
12.
go back to reference A. Glezer, M.D. Bronstein, Approach to the patient with persistent hyperprolactinemia and negative sellar imaging. J. Clin. Endocrinol. Metab. 97, 2211–2216 (2012)CrossRef A. Glezer, M.D. Bronstein, Approach to the patient with persistent hyperprolactinemia and negative sellar imaging. J. Clin. Endocrinol. Metab. 97, 2211–2216 (2012)CrossRef
13.
go back to reference A. Colao, G. Vitale, P. Cappabianca, F. Briganti, A. Ciccarelli, M. De Rosa, S. Zarrilli, G. Lombardi, Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J. Clin. Endocrinol. Metab. 89, 1704–1711 (2004)CrossRef A. Colao, G. Vitale, P. Cappabianca, F. Briganti, A. Ciccarelli, M. De Rosa, S. Zarrilli, G. Lombardi, Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J. Clin. Endocrinol. Metab. 89, 1704–1711 (2004)CrossRef
14.
go back to reference A.H. Zamanipoor Najafabadi, I.M. Zandbergen, F. de Vries, L.H.A. Broersen, M.E. van den Akker-van Marle, A.M. Pereira, W.C. Peul, O.M. Dekkers, W.R. van Furth, N.R. Biermasz, Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 105, e32–e41 (2020)CrossRef A.H. Zamanipoor Najafabadi, I.M. Zandbergen, F. de Vries, L.H.A. Broersen, M.E. van den Akker-van Marle, A.M. Pereira, W.C. Peul, O.M. Dekkers, W.R. van Furth, N.R. Biermasz, Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 105, e32–e41 (2020)CrossRef
15.
go back to reference D. Maiter, E. Delgrange, Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur. J. Endocrinol. 170, R213–R227 (2014)CrossRef D. Maiter, E. Delgrange, Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur. J. Endocrinol. 170, R213–R227 (2014)CrossRef
Metadata
Title
True hyperprolactinemia in men without visible pituitary adenoma
Authors
Ilan Shimon
Yaron Rudman
Yossi Manisterski
Alex Gorshtein
Hiba Masri
Hadar Duskin-Bitan
Publication date
01-06-2021
Publisher
Springer US
Published in
Endocrine / Issue 3/2021
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-021-02624-1

Other articles of this Issue 3/2021

Endocrine 3/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine